Status:
RECRUITING
Local Inflammation in Arrhythmogenic Right Ventricular Cardiomyopathy
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Arrhythmogenic Right Ventricular Dysplasia
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
The understanding of ARVC pathophysiology remains incomplete. Several clues indicate that disease progression is mediated through inflammation. The present study aim to document the feasibility of det...
Detailed Description
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a heritable condition characterized by right ventricular (RV) dilatation/dysfunction and malignant ventricular arrhythmias. The understanding ...
Eligibility Criteria
Inclusion
- For cases:
- Arrhythmogenic right ventricular dysplasia diagnosed (according to 2010 Task Force Criteria)
- Admitted for right ventricle electrophysiologic mapping
- For controls \* Admitted for ablation procedures (accessory pathway, atrial flutter) on otherwise healthy hearts.
Exclusion
- Diagnostic of systemic chronic inflammatory disease
- Presence of possible or proven cardiac involvement of an inflammatory disease, an acute or chronic infectious disease.
- Taking immunosuppressant or immunomodulating medications
Key Trial Info
Start Date :
February 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05209776
Start Date
February 1 2022
End Date
February 1 2026
Last Update
October 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Toulouse University Hospital Center
Toulouse, France